Adhésion thérapeutique et collaboration médecin-pharmacien. L’exemple du patient avec néphropathie diabétique

Schneider, Marie‐Paule; Bandiera, Carole; Dotta-Celio, Jennifer; Zanchi, Anne

doi:10.53738/revmed.2020.16.697.1210

Cited by 3 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Siscare is offered by the interprofessional medication adherence program (IMAP) SA, a practice change facilitator/purveyor that has been developing smart and innovation solutions for a network of community pharmacies, since 2011, 25 based on adaptations of the IMAP that was developed and implemented with various chronic populations, such as hypertension and patients with HIV, through a physician-pharmacist-nurse collaboration at the IMAP starting in 1995. 26,27…”

Section: Interventionmentioning

confidence: 99%

Building Interprofessional Collaborative Practices Through a Support Program for Patients With Type 2 Diabetes in Primary Care

Bawab

Moullin

Jotterand

et al. 2023

J Contin Educ Health Prof

View full text Add to dashboard Cite

show abstract

Section: Interventionmentioning

confidence: 99%

Building Interprofessional Collaborative Practices Through a Support Program for Patients With Type 2 Diabetes in Primary Care

Bawab

Moullin

Jotterand

et al. 2023

J Contin Educ Health Prof

View full text Add to dashboard Cite

show abstract

“…Les autres causes d'HTA secondaire peuvent être évoquées selon la clinique et en présence d'une HTA résistante, après avoir écarté des troubles de l'adhésion thérapeutique très fréquente lors de polypharmacie. 17 Un échodoppler des reins et des artères rénales est donc recommandé chez les patients diabétiques et hypertendus, car même lorsque la fonction rénale est normale ou en l'absence d'albuminurie, l'index de résistance rénal (en particulier, chez les jeunes) est un marqueur précoce de l'atteinte rénale. 18 Enfin, chez tous les patients diabétiques, il faut être attentif au risque d'hypotension orthostatique secondaire à une dysautonomie.…”

Section: Outils Diagnostiquesunclassified

En quoi la prise en charge de l’hypertendu diabétique est-elle différente?

Teso¹,

Lamine²,

Zanchi³

et al. 2022

Revue Médicale Suisse

View full text Add to dashboard Cite

En quoi la prise en charge de l'hypertendu diabétique est-elle différente ?L'hypertension artérielle (HTA) est fréquente chez les patients diabétiques et augmente de manière considérable les complications du diabète et le risque cardiovasculaire. Il est donc particulièrement important de dépister de manière systématique et de traiter l'HTA chez ces patients. Les cibles tensionnelles dans cette population (< 130/80 mmHg) doivent être adaptées à l'âge et aux comorbidités. Dans la population diabétique, l'arsenal thérapeutique s'est élargi au-delà des inhibiteurs du système rénine-angiotensine-aldostérone, avec des traitements qui influencent le pronostic cardiovasculaire et rénal, comme c'est le cas pour les inhibiteurs du SGLT2, les agonistes des récepteurs du GLP-1 et, bientôt, la finérénone. How is the management of diabetic hypertensive patients different?High blood pressure (HBP) is common in diabetic patients and significantly increases complications of diabetes and cardiovascular risk. It is therefore particularly important to routinely screen and treat HBP in these patients. Blood pressure targets in this population (<130/80mmHg) should be adapted to age and comorbidities.The therapeutic strategy has expanded beyond renin-angiotensinaldosterone system inhibitors in the diabetic population, with treatments which decrease cardiovascular and renal risk, such as SGLT2 inhibitors, GLP-1 receptor agonists, and soon finerenone.

show abstract

“…A well-structured multidisciplinary collaboration benefits the quality of care, patient engagement, patient safety and provides many benefits for both staff and organization (Morley & Cashell, 2017). Improvement of multidisciplinary collaboration between community pharmacists and GPs has shown to decrease the number of drug-related problems and to enhance medication adherence as well as clinical outcomes in a variety of patient groups (Alfian et al, 2021;Hwang et al, 2017;Schneider et al, 2020). Therefore, complex problems, such as medication non-adherence, are best supported by a joint approach by different healthcare providers (Braithwaite & Westbrook, 2005;Robbins et al, 2012).…”

Section: Multidisciplinary Collaborationmentioning

confidence: 99%

Implementation and scalability of primary care interventions to improve patients medication use

Hogervorst

View full text Add to dashboard Cite

Treatment with medicines is the single most used method for treating patients with chronic conditions and to prevent further damage of the disease. The use of medicines is agreed upon between healthcare provider and patient and is only effective if used correctly. However, medication use is problematic for many patients and drug-related problems are common when patients do not succeed in following their treatment. Non-adherence to treatment regimens is a major drug-related problem in 44 to 77% of chronic medication users. Many evidence-based medication adherence interventions have been developed for healthcare providers to better support patients in taking their medication. These interventions are often complex, as they must be tailored to diverse patient populations, rely on close collaboration between different healthcare providers, and require continuous monitoring of non-adherent patients. This complexity means that for these interventions to be effective, they must be continuously available for patients by a multidisciplinary team of healthcare providers. As such, they need to be fully integrated into daily clinical practice systems in a (cost-)effective manner. However, so far, their implementation is often lacking. Integrating complex interventions into daily clinical practice is complex. It requires tailoring the intervention to the context in which they will be implemented, which requires using implementation strategies that fit within the context. In order to do so, detailed information about the setting and its context is required. However, current publications on interventions generally do not provide sufficient details about the implementation and the context to be reproduced in different settings. This tailoring can be supported by dissemination and implementation science methods, which offer different models and theories on implementing complex interventions into daily clinical practice. Throughout this thesis, we provide insight into how medication use of patients with a chronic disease can be optimized by improving the implementation and scale-up of medication adherence interventions in primary care. This was described in five chapters (chapters 2 to 6). We discussed our main findings and drew conclusions in chapter 7.

show abstract

Adhésion thérapeutique et collaboration médecin-pharmacien. L’exemple du patient avec néphropathie diabétique

Cited by 3 publications

References 5 publications

Building Interprofessional Collaborative Practices Through a Support Program for Patients With Type 2 Diabetes in Primary Care

Building Interprofessional Collaborative Practices Through a Support Program for Patients With Type 2 Diabetes in Primary Care

En quoi la prise en charge de l’hypertendu diabétique est-elle différente?

Implementation and scalability of primary care interventions to improve patients medication use

Contact Info

Product

Resources

About